Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Mepolizumab HES Study Group"'
Autor:
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group, Baccarani M
Publikováno v:
New England Journal of Medicine. 358:1215-1228
The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115ff08d425c82beffaa08248238cd27
https://doi.org/10.1056/nejmoa070812
https://doi.org/10.1056/nejmoa070812
